Antimicrobial Peptides of Skin and Oral Mucosa

Innate Immune System of Skin and Oral Mucosa: Properties and Impact in Pharmaceutics, Cosmetics, and Personal Care Products

Volumn , Issue , 2011, Pages 117-144

  Chung, Whasun O ^a   Dommisch, Henrik ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

AMPs in epidermal and oral innate immunity therapeutics, skin, oral inflammatory diseases; AMPs in skin infections, wound healing nonpathogenic commensal bacteria, skin homeostasis; Antimicrobial peptides of skin, oral mucosa chemical barrier, antimicrobial peptides (AMPs)

Indexed keywords

EID: 84886030126     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118025338.ch7     Document Type: Chapter

References (215)

1. Dale BA. Periodontal epithelium: a newly recognized role in health and disease. Periodontol. 2000, 2002;30:70-78.
2. Ganz T. Defensins: antimicrobial peptides of vertebrates. C. R. Biol. 2004;327(6):539-549.
3. Harder J, et al. A peptide antibiotic from human skin. Nature 1997;387(6636):861.
4. Harder J, et al. Isolation and characterization of human beta-defensin-3: a novel human inducible peptide antibiotic. J. Biol. Chem. 2001;276(8):5707-5713.
5. Ong PY, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 2002;347(15):1151-1160.
6. Lehrer RI. Primate defensins. Nat. Rev. Microbiol. 2004;2(9):727-738.
7. Premratanachai P, et al. Expression and regulation of novel human beta-defensins in gingival keratinocytes. Oral Microbiol. Immunol. 2004;19(2):111-117.
8. Abiko Y, et al. Role of beta-defensins in oral epithelial health and disease. Med. Mol. Morphol. 2007; 40(4):179-184.
9. Hancock RE, Scott MG. The role of antimicrobial peptides in animal defenses. Proc. Natl. Acad. Sci. USA 2000;97(16):8856-8861.
10. Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nat. Immunol. 2005;6(6):551-557.
11. Chung WO, et al. Expression of defensins in gingiva and their role in periodontal health and disease. Curr. Pharm. Des. 2007;13(30):3073-3083.
12. Dale BA, Brown PS, Wells NJ. Picture talk: effective communication with participants as a critical element in oral health research. J. Dent. Res. 2003;82(9):669-670.
13. Buchmann R, et al. Amplified crevicular leukocyte activity in aggressive periodontal disease. J. Dent. Res. 2002;81(10):716-721.
14. Hatakeyama S, et al. Expression pattern of adhesion molecules in junctional epithelium differs from that in other gingival epithelia. J. Periodontal. Res. 2006;41(4):322-328.
15. Schroeder HE, Rossinsky K, Listgarten MA. Human junctional epithelium as a pathway for inflammatory exudation. J. Biol. Buccale 1989;17(3):147-157.
16. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann. Periodontol. 1999;4(1):1-6.
17. Socransky SS, Haffajee AD. Microbiology of periodontal disease. In: Lindhe J,editor. Clinical Periodontology and Implant Dentistry. Oxford: Blackwell, 2003.
18. Socransky SS, et al. Microbial complexes in subgingival plaque. J. Clin. Periodontol. 1998; 25(2):134-144.
19. Kinane DF, Hart TC. Genes and gene polymorphisms associated with periodontal disease. Crit. Rev. Oral Biol. Med. 2003;14(6):430-449.
20. Loos, BG, John RP, Laine ML. Identification of genetic risk factors for periodontitis and possible mechanisms of action. J. Clin. Periodontol. 2005;32(Suppl. 6):159-179.
21. Michalowicz BS, et al. Periodontal findings in adult twins. J. Periodontol. 1991;62(5):293-299.
22. Michalowicz BS, et al. Evidence of a substantial genetic basis for risk of adult periodontitis. J. Periodontol. 2000;71(11):1699-1707.
23. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet 2005;366(9499): 1809-1820.
24. Jansen PA, et al. Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. PLoS One 2009;4(3):e472-e475.
25. Wingens M, et al. Induction of SLPI (ALP/HUSI-I) in epidermal keratinocytes. J. Invest. Dermatol. 1998;111(6):996-1002.
26. Nonomura K, et al. Upregulation of elafin/SKALP gene expression in psoriatic epidermis. J. Invest. Dermatol. 1994;103(1):88-91.
27. Boguniewicz M, Leung DY. Atopic dermatitis. J. Allergy Clin. Immunol. 2006;117(2 Suppl. Mini- Primer):S475-S480.
28. Leung DY, et al. New insights into atopic dermatitis. J. Clin. Invest. 2004;113(5):651-657.
29. McGirt LY, Beck LA. Innate immune defects in atopic dermatitis. J. Allergy Clin. Immunol. 2006;118 (1):202-208.
30. Howell MD. The role of human beta-defensins and cathelicidins in atopic dermatitis. Curr. Opin. Allergy Clin. Immunol. 2007;7(5):413-417.
31. Chen X, et al. Synergistic effect of antibacterial agents human beta-defensins, cathelicidin LL-37 and lysozyme against Staphylococcus aureus and Escherichia coli. J. Dermatol. Sci. 2005; 40(2):123-132.
32. Lehrer RI, Ganz T. Defensins of vertebrate animals. Curr. Opin. Immunol. 2002;14(1):96-102.
33. vanWetering S, et al. Defensins: key players or bystanders in infection, injury, and repair in the lung? J. Allergy Clin. Immunol. 1999;104(6):1131-1138.
34. Lehrer RI, Lichtenstein AK, Ganz T. Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu. Rev. Immunol. 1993;11:105-128.
35. Selsted ME, Miller SI, Henschen AH, Ouellette AJ. Enteric defensins: antibiotic peptide components of intestinal host defense. J. Cell Biol. 1992;118:929-936.
36. Ouellette AJ. Paneth cell antimicrobial peptides and the biology of the mucosal barrier. Am. J. Physiol. 1999;277:G257-G261.
37. Wilson CL, et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999;286(5437):113-117.
38. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc. Natl. Acad. Sci. USA 1998;95:588-593.
39. Dale BA, Krisanaprakornkit S. Defensin antimicrobial peptides in the oral cavity. J. Oral. Pathol. Med. 2001;30(6):321-327.
40. LiuL, et al. Thehuman beta-defensin-1 and alpha-defensins are encoded by adjacent genes: two peptide families with differing disulfide topology share a common ancestry. Genomics 1997;43(3):316-320.
41. Friedrich CL, et al. Structure and mechanism of action of an indolicidin peptide derivative with improved activity against Gram-positive bacteria. J. Biol. Chem. 2001;276(26):24015-24022.
42. ValoreEV, et al. Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J. Clin. Invest. 1998;101(8):1633-1642.
43. Cole AM, Dewan P, Ganz T. Innate antimicrobial activity of nasal secretions. Infect. Immun. 1999;67:3267-3275.
44. Sahasrabudhe KS, Kimball JR, Morton T, Weinberg W, Dale BA. Expression of the antimicrobial peptide, human b-defensin 1, in duct cells of minor salivary glands and detection in saliva. J. Dental Res. 2000;79:1669-1674.
45. Diamond DL, et al. Detection of beta-defensins secreted by human oral epithelial cells. J. Immunol. Methods 2001;256(1-2):65-76.
46. Diamond G, Russell JP, Bevins CL. Inducible expression of an antibiotic peptide gene in lipopolysaccharide-challenged tracheal epithelial cells. Proc. Natl. Acad. Sci. USA 1996;93(10): 5156-5160.
47. Krisanaprakornkit S, et al. Expression of the peptide antibiotic human beta-defensin 1 in cultured gingival epithelial cells and gingival tissue. Infect. Immun. 1998;66(9):4222-4228.
48. Zhao C,Wang I, Lehrer RI.Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett. 1996;396(2-3):319-322.
49. Mathews M, et al. Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect. Immun. 1999;67(6):2740-2745.
50. O'Neil DA, et al. Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J. Immunol. 1999;163(12):6718-6724.
51. Krisanaprakornkit S, et al. Inducible expression of human beta-defensin 2 by Fusobacterium nucleatum in oral epithelial cells: multiple signaling pathways and role of commensal bacteria in innate immunity and the epithelial barrier. Infect. Immun. 2000;68(5):2907-2915.
52. Harder J, et al. Mucoid Pseudomonas aeruginosa, TNF-alpha, and IL-1beta, but not IL6, induce human beta-defensin-2 in respiratory epithelia. Am. J. Respir. Cell. Mol. Biol. 2000;22(6):714-721.
53. Chung WO, Dale BA. Innate immune response of oral and foreskin keratinocytes: utilization of different signaling pathways by various bacterial species. Infect. Immun. 2004;72(1):352-358.
54. Dommisch H, et al. Protease-activated receptor 2 mediates human beta-defensin 2 and CC chemokine ligand 20 mRNA expression in response to proteases secreted by Porphyromonas gingivalis. Infect. Immun. 2007;75(9):4326-4333.
55. Dale BA, et al. Localized antimicrobial peptide expression in human gingiva. J. Periodontal Res. 2001;36(5):285-294.
56. Dommisch H, et al. Differential gene expression of human beta-defensins (hBD-1, -2, -3) in inflammatory gingival diseases. Oral Microbiol. Immunol. 2005;20(3):186-190.
57. Dunsche A, et al. The novel human beta-defensin-3 is widely expressed in oral tissues. Eur. J. Oral Sci. 2002;110(2):121-124.
58. Schutte BC, et al. Discovery of five conserved beta-defensin gene clusters using a computational search strategy. Proc. Natl. Acad. Sci. USA 2002;99(4):2129-2133.
59. Yang D, Chertov O, Oppenheim JJ. The role of mammalian antimicrobial peptides and proteins in awakening of innate host defenses and adaptive immunity. Cell. Mol. Life Sci. 2001;58(7):978-989.
60. Scott MG, et al. An alpha-helical cationic antimicrobial peptide selectively modulates macrophage responses to lipopolysaccharide and directly alters macrophage gene expression. J. Immunol. 2000;165(6):3358-3365.
61. Tani K, et al. Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int. Immunol. 2000;12(5):691-700.
62. Yang D, et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999;286(5439):525-528.
63. Boniotto M, et al. Human beta-defensin 2 induces a vigorous cytokine response in peripheral blood mononuclear cells. Antimicrob. Agents Chemother. 2006;50(4):1433-1441.
64. Niyonsaba F, et al. Epithelial cell-derived antibacterial peptides human beta-defensins and cathelicidin: multifunctional activities on mast cells. Curr. Drug Targets Inflamm. Allergy 2003;2 (3):224-231.
65. Niyonsaba F, et al. The human beta-defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. J. Immunol. 2005;175(3):1776-1784.
66. Yang D, et al. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol. 2002;23(6):291-296.
67. Dommisch H, et al. P. gingivalis-induced gene expression of MIP-3a/CCL20 in human oral keratinocytes is dependent on PLC, p38/MAPK, and NF-kB-mediated pathways. Innate Immun. 2010;16(4):226-34.
68. Chung WO, Dale BA. Differential utilization of NFkB signaling pathways for gingival epithelial cell responses to oral commensal and pathogenic bacteria. Oral Microbiol. Immunol. 2008;23:119-126.
69. Diamond G, et al. Transcriptional regulation of beta-defensin gene expression in tracheal epithelial cells. Infect. Immun. 2000;68(1):113-119.
70. SchroderNW, et al. Involvement of lipopolysaccharide binding protein, CD14, andToll-like receptors in the initiation of innate immune responses by Treponema glycolipids. J. Immunol. 2000;165 (5):2683-2693.
71. Krisanaprakornkit S, Kimball JR, Dale BA. Regulation of human beta-defensin-2 in gingival epithelial cells: the involvement of mitogen-activated protein kinase pathways, but not the NFkappaB transcription factor family. J. Immunol. 2002;168(1):316-324.
72. Chung WO, et al. Protease-activated receptor signaling increases epithelial antimicrobial peptide expression. J. Immunol. 2004;173(8):5165-5170.
73. Niyonsaba F, et al. Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J. Invest Dermatol. 2007;127(3):594-604.
74. Zaiou M, Nizet V, Gallo RL. Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence. J. Invest. Dermatol. 2003;120(5):810-816.
75. Zanetti M, et al. Structure and biology of cathelicidins. Adv. Exp. Med. Biol. 2000;479:203-218.
76. Kenshi Y, Gallo RL. Antimicrobial peptides in human skin disease. Eur. J. Dermatol. 2008; 18(1):11-21.
77. Frohm M, et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J. Biol. Chem. 1997;272(24):15258-15263.
78. Frohm Nilsson M, et al. The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect. Immun. 1999;67(5):2561-2566.
79. Murakami M, et al. Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva. J. Dent. Res. 2002;81(12):845-850.
80. Dale BA, Fredericks LP. Antimicrobial peptides in the oral environment: expression and function in health and disease. Curr. Issues Mol. Biol. 2005;7(2):119-133.
81. Tonetti MS, et al. Localized expression of mRNA for phagocyte-specific chemotactic cytokines in human periodontal infections. Infect. Immun. 1994;62(9):4005-4014.
82. HenzlerWildman KA, Lee DK, Ramamoorthy A. Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry 2003;42(21):6545-6558.
83. Howell MD, et al. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J. Immunol. 2004;172(3):1763-1767.
84. Lopez-Garcia B, et al. Antifungal activity of cathelicidins and their potential role in Candida albicans skin infection. J. Invest. Dermatol. 2005;125(1):108-115.
85. Nizet V, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001;414(6862):454-457.
86. Altman H, et al. In vitro assessment of antimicrobial peptides as potential agents against several oral bacteria. J. Antimicrob. Chemother. 2006;58(1):198-201.
87. Braff MH, et al. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J. Immunol. 2005;174(7): 4271-4278.
88. Yang D, et al. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J. Leukoc. Biol. 2000;68(1):9-14.
89. Yang D, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 2000;192(7):1069-1074.
90. Cunliffe RN. Alpha-defensins in the gastrointestinal tract. Mol. Immunol. 2003;40(7):463-467.
91. Ganz T, Lehrer RI. Defensins. Curr. Opin. Immunol. 1994;6(4):584-589.
92. Ganz T, et al. Defensins: natural peptide antibiotics of human neutrophils. J. Clin. Invest. 1985;76 (4):1427-1435.
93. Mizukawa N, et al. Levels of human defensin-1, an antimicrobial peptide, in saliva of patients with oral inflammation. Oral Surg. Oral. Med. Oral Pathol. Oral Radiol. Endod. 1999;87(5):539-543.
94. Goebel C, et al. Determination of defensin HNP-1, HNP-2, and HNP-3 in human saliva by using LC/ MS. Peptides 2000;21(6):757-765.
95. Lehrer RI, et al. Modulation of the in vitro candidacidal activity of human neutrophil defensins by target cell metabolism and divalent cations. J. Clin. Invest. 1988;81(6):1829-1835.
96. Chung WO, et al. Expression of defensins in gingiva and their role in periodontal health and disease. Curr. Pharm. Design 2007;13:3073-3083.
97. Kinane DF, et al. Human variability in innate immunity. Periodontol 2000 2007;45:14-34.
98. Ganz T, et al. Microbicidal/cytotoxic proteins of neutrophils are deficient in two disorders: Chediak-Higashi syndrome and "specific" granule deficiency. J. Clin. Invest. 1988;82(2):552-556.
99. Putsep K, et al. Deficiency of antibacterial peptides in patients with morbusKostmann: an observation study. Lancet 2002;360(9340):1144-1149.
100. Carlsson G, et al. Periodontal disease in patients from the original Kostmann family with severe congenital neutropenia. J. Periodontol. 2006;77(4):744-751.
101. Tao R, et al. Salivary antimicrobial peptide expression and dental caries experience in children. Antimicrob. Agents Chemother. 2005;49(9):3883-3888.
102. Dale BA, et al. Oral antimicrobial peptides and biological control of caries. BMC Oral Health 2006; 6(Suppl. 1): S13.
103. Dork T, Stuhrmann M. Polymorphisms of the human beta-defensin-1 gene. Mol. Cell. Probes, 1998;12(3):171-173.
104. Jurevic RJ, et al. Single-nucleotide polymorphisms and haplotype analysis in betadefensin genes in different ethnic populations. Genet. Test 2002;6(4):261-269.
105. Vatta S, et al. Human beta-defensin 1 gene: six new variants. Hum. Mutat. 2000;15(6):582-583.
106. Jurevic RJ, et al. Single-nucleotide polymorphisms (SNPs) in human beta-defensin 1: highthroughput SNP assays and association with candida carriage in type i diabetics and nondiabetic controls. J. Clin. Microbiol. 2003;41(1):90-96.
107. Hollox EJ, Armour JA, Barber JC. Extensive normal copy number variation of a beta-defensin antimicrobial-gene cluster. Am. J. Hum. Genet. 2003;73(3):591-600.
108. Linzmeier RM, Ganz T. Human defensin gene copy number polymorphisms: comprehensive analysis of independent variation in alpha- and beta-defensin regions at 8p22-p23. Genomics 2005; 86(4):423-430.
109. Lu Q, et al. Expression of human beta-defensins-1 and -2 peptides in unresolved chronic periodontitis. J. Periodontal Res. 2004;39(4):221-227.
110. Lu Q, et al. Expression of human beta-defensin-3 in gingival epithelia. J. Periodontal Res. 2005; 40(6):474-481.
111. Bissell J, et al. Expression of beta-defensins in gingival health and in periodontal disease. J. Oral Pathol. Med. 2004;33(5):278-285.
112. Hosokawa I, et al. Innate immune peptide LL-37 displays distinct expression pattern from betadefensins in inflamed gingival tissue. Clin. Exp. Immunol. 2006;146(2):218-225.
113. Vardar-Sengul S, et al.Humanbeta defensin-1 and -2 expression in the gingiva of patients with specific periodontal diseases. J. Periodontal Res. 2007;42(5):429-437.
114. Kesting MR, et al. Expression profile of human beta-defensin 3 in oral squamous cell carcinoma. Cancer Invest. 2009;27(5):575-581.
115. Wenghoefer M, et al. Decreased gene expression of human beta-defensin-1 in the development of squamous cell carcinoma of the oral cavity. Int. J. Oral Maxillofac. Surg. 2008;37(7):660-663.
116. Wenghoefer M, et al. Nuclear hBD-1 accumulation in malignant salivary gland tumours.BMCCancer 2008;8:290.
117. Ouhara K, et al. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, beta-defensins and LL37, produced by human epithelial cells. J. Antimicrob. Chemother. 2005;55(6):888-896.
118. Joly S, et al. Human beta-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J. Clin. Microbiol. 2004;42(3):1024-1029.
119. Nishimura E, et al. Oral streptococci exhibit diverse susceptibility to human betadefensin-2: antimicrobial effects of hBD-2 on oral streptococci. Curr. Microbiol. 2004;48(2):85-87.
120. Guthmiller JM, et al. Susceptibilities of oral bacteria and yeast to mammalian cathelicidins. Antimicrob. Agents Chemother. 2001;45(11):3216-3219.
121. Feng Z, et al. Human beta-defensins: differential activity against candidal species and regulation by Candida albicans. J. Dent. Res. 2005;84(5):445-450.
122. Daher KA, Selsted ME, Lehrer RI. Direct inactivation of viruses by human granulocyte defensins. J. Virol. 1986;60(3):1068-1074.
123. Quinones-Mateu ME, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 2003;17(16):F39-F48.
124. Sun L, et al. Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J. Virol. 2005;79(22):14318-14329.
125. Feng Z, et al. Cutting edge: human beta defensin 3: a novel antagonist of the HIV-1 coreceptor CXCR4. J. Immunol. 2006;177(2):782-786.
126. Maisetta G, et al. Activity of human beta-defensin 3 alone or combined with other antimicrobial agents against oral bacteria. Antimicrob. Agents Chemother. 2003;47(10):3349-3351.
127. Eckert RL, et al. S100 proteins in the epidermis. J. Invest. Dermatol. 2004;123(1):23-33.
128. Harder J, Schroder JM. Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteins. J. Leukoc. Biol. 2005;77(4):476-486.
129. Steinstraesser L, et al. Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides. Retrovirology 2005;2:2.
130. Liu AY, et al. Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. J. Invest. Dermatol. 2002;118(2):275-281.
131. de Jongh GJ, et al. High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J. Invest. Dermatol. 2005;125(6):1163-1173.
132. Hollox EJ, et al. Psoriasis is associated with increased beta-defensin genomic copy number. Nat. Genet. 2008;40(1):23-25.
133. Kim E, et al. Single nucleotide polymorphisms and the haplotype in the DEFB1 gene are associated with atopic dermatitis in a Korean population. J. Dermatol. Sci. 2009;54(1):25-30.
134. Henseler T, Christophers E. Disease concomitance in psoriasis. J. Am. Acad. Dermatol. 1995;32 (6):982-986.
135. Murakami M, et al. Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J. Invest. Dermatol. 2002;119(5):1090-1095.
136. Kaus A, et al. Host defence peptides in human burns. Burns 2008;34(1):32-40.
137. Milner SM, et al. Expression of human beta defensin 2 in thermal injury. Burns 2004;30(7):649-654.
138. Poindexter BJ, et al. Localization of antimicrobial peptides in normal and burned skin. Burns 2006; 32(4):402-407.
139. Gambichler T, et al. Significant upregulation of antimicrobial peptides and proteins in lichen sclerosus. Br. J. Dermatol. 2009;161(5):1136-1142.
140. Eisendle K, et al. Possible role of Borrelia burgdorferi sensu lato infection in lichen sclerosus. Arch. Dermatol. 2008;144(5):591-598.
141. Lusitani D, Malawista SE, Montgomery RR. Borrelia burgdorferi are susceptible to killing by a variety of human polymorphonuclear leukocyte components. J. Infect. Dis. 2002;185(6): 797-804.
142. Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch. Intern. Med. 1992;152(3):610-616.
143. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation: basis for prevention. Diabetes Care 1990;13(5):513-521.
144. Apelqvist J, Larsson J. What is the most effective way to reduce incidence of amputation in the diabetic foot? Diabetes Metab. Res. Rev. 2000;16(Suppl. 1):S75-S83.
145. Hirsch T, et al. Human beta-defensin-3 promotes wound healing in infected diabetic wounds. J. Gene Med. 2009;11(3):220-228.
146. Goldstein EJ, Citron DM, Nesbit CA. Diabetic foot infections: bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Diabetes Care 1996;19 (6):638-641.
147. Maisetta G, et al. In vitro bactericidal activity of human beta-defensin 3 against multidrug-resistant nosocomial strains. Antimicrob. Agents Chemother. 2006;50(2):806-809.
148. Supp DM, et al. Antibiotic resistance in clinical isolates of Acinetobacter baumannii, Pseudomonas aeruginosa, and Staphylococcus aureus does not impact sensitivity to human beta-defensin-4. Burns 2009;35(7):949-955.
149. Sorensen OE, et al. Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor. J. Clin. Invest. 2006;116(7):1878-1885.
150. Gordon YJ, Romanowski EG, McDermott AM. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr. Eye Res. 2005;30(7):505-515.
151. McPhee JB, Hancock RE. Function and therapeutic potential of host defence peptides. J. Pept. Sci. 2005;11(11):677-687.
152. Boman HG. Antibacterial peptides: basic facts and emerging concepts. J. Intern. Med. 2003; 254(3):197-215.
153. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 2006;24(12):1551-1557.
154. Sang Y, Blecha F. Antimicrobial peptides and bacteriocins: alternatives to traditional antibiotics. Anim. Health Res. Rev. 2008;9(2):227-235.
155. Yang D, et al. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu. Rev. Immunol. 2004;22:181-215.
156. Puklo M, et al. Analysis of neutrophil-derived antimicrobial peptides in gingival crevicular fluid suggests importance of cathelicidin LL-37 in the innate immune response against periodontogenic bacteria. Oral Microbiol. Immunol. 2008;23(4):328-335.
157. Yang D, et al. Many chemokines including CCL20/MIP-3alpha display antimicrobial activity. J. Leukoc. Biol. 2003;74(3):448-455.
158. Chang TL, et al. Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J. Clin. Invest. 2005;115(3):765-773.
159. WangW, et al. Activity of alpha- and theta-defensins against primary isolates of HIV1. J. Immunol. 2004;173(1):515-520.
160. Zhang L, et al. Contribution of human alpha-defensin-1, -2, and -3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 2002;98(5595):995-1000.
161. Fu LM. The potential of human neutrophil peptides in tuberculosis therapy. Int. J. Tuberc. Lung Dis., 2003;7(11):1027-1032.
162. Sharma S, Verma I, Khuller GK. Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis. Antimicrob. Agents Chemother. 2001;45(2):639-640.
163. Shu Q, et al. Protection against Pseudomonas aeruginosa pneumonia and sepsis-induced lung injury by overexpression of beta-defensin-2 in rats. Shock 2006;26(4):365-371.
164. Oppenheim JJ, et al. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann. Rheum. Dis. 2003;62(Suppl. 2):ii17-ii21.
165. Mickels N, et al. Clinical and microbial evaluation of a histatin-containing mouthrinse in humans with experimental gingivitis. J. Clin. Periodontol. 2001;28(5):404-410.
166. ReddyKV,Yedery RD, Aranha C. Antimicrobial peptides: premises and promises. Int. J. Antimicrob. Agents 2004;24(6):536-547.
167. Rothstein DM, et al. Histatin-derived peptides: potential agents to treat localised infections. Expert Opin. Emerg. Drugs 2002;7(1):47-59.
168. Tsai H, Bobek LA. Human salivary histatins: promising anti-fungal therapeutic agents. Crit. Rev. Oral Biol. Med. 1998;9(4):480-497.
169. Van Dyke T, et al. Clinical and microbial evaluation of a histatin-containing mouthrinse in humans with experimental gingivitis: a phase-2 multi-center study. J. Clin. Periodontol. 2002;9(2):168-176.
170. Dommisch H, et al. Immune regulatory functions of human beta-defensin-2 in odontoblast-like cells. Int. Endod. J. 2007;40(4):300-307.
171. Niyonsaba F, Ogawa H, Nagaoka I. Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils. Immunology 2004;111(3):273-281.
172. Cotter PD, Hill C, Ross RP. Bacteriocins: developing innate immunity for food. Nat. Rev. Microbiol. 2005;3(10):777-788.
173. Willey JM, van der Donk WA. Lantibiotics: peptides of diverse structure and function. Annu. Rev. Microbiol. 2007;61:477-501.
174. De Vuyst L, Leroy F. Bacteriocins from lactic acid bacteria: production, purification, and food applications. J. Mol. Microbiol. Biotechnol. 2007;13(4):194-199.
175. Sit CS, Vederas JC. Approaches to the discovery of new antibacterial agents based on bacteriocins. Biochem. Cell. Biol. 2008;86(2):116-123.
176. Dufour A, et al. The biology of lantibiotics from the lacticin 481 group is coming of age. FEMS Microbiol. Rev. 2007;31(2):134-167.
177. Kruszewska D, et al. Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J. Antimicrob. Chemother. 2004;54(3):648-653.
178. Nackaerts O, et al. Replacement therapy for periodontitis: pilot radiographic evaluation in a dog model. J. Clin. Periodontol. 2008;35(12):1048-1052.
179. Teughels W, et al. Guiding periodontal pocket recolonization: a proof of concept. J. Dent. Res. 2007;86(11):1078-1082.
180. Shimauchi H, et al. Improvement of periodontal condition by probiotics with Lactobacillus salivarius WB21: a randomized, double-blind, placebo-controlled study. J. Clin. Periodontol. 2008;35(10): 897-905.
181. Aerts AM, et al. The antifungal activity of RsAFP2, a plant defensin from Raphanus sativus, involves the induction of reactive oxygen species in Candida albicans. J. Mol. Microbiol. Biotechnol. 2007; 13(4):243-247.
182. De Samblanx GW, et al. Mutational analysis of a plant defensin from radish (Raphanus sativus L.) reveals two adjacent sites important for antifungal activity. J. Biol. Chem. 1997;272(2): 1171-1179.
183. Madeo F, Frohlich E, Frohlich KU. A yeast mutant showing diagnostic markers of early and late apoptosis. J. Cell. Biol. 1997;139(3):729-734.
184. Thevissen K, et al. Therapeutic potential of antifungal plant and insect defensins. Drug Discov. Today 2007;12(21-22):966-971.
185. Andres E, Dimarcq JL. Cationic anti-microbial peptides: from innate immunity study to drug development. Rev. Med. Interne 2004;25(9):629-635.
186. Aguiar GP, et al.AReviewof the biological and clinical aspects of radiation caries. J. Contemp. Dent. Pract. 2009;10(4):83-89.
187. Muta T, et al. Tachyplesins isolated from hemocytes of Southeast Asian horseshoe crabs (Carcinoscorpius rotundicauda and Tachypleus gigas): identification of a new tachyplesin, tachyplesin III, and a processing intermediate of its precursor. J. Biochem. 1990;108(2): 261-266.
188. Masuda M, et al. A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12, Lys7]polyphemusin II). Biochem. Biophys. Res. Commun. 1992;189(2):845-850.
189. Tamamura H, et al. Antimicrobial activity and conformation of tachyplesin I and its analogs. Chem. Pharm. Bull. (Tokyo) 1993;41(5):978-980.
190. Miyasaki KT, Lehrer RI. Beta-sheet antibiotic peptides as potential dental therapeutics. Int. J. Antimicrob. Agents. 1998;9(4):269-280.
191. Giovannini MG, et al. Biosynthesis and degradation of peptides derived from Xenopus laevis prohormones. Biochem. J. 1987;243(1):113-120.
192. ZasloffM. Magainins: a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc. Natl. Acad. Sci. USA 1987;84 (15):5449-5453.
193. Gottler LM, Ramamoorthy A. Structure, membrane orientation, mechanism, and function of pexiganan: a highly potent antimicrobial peptide designed from magainin. Biochim. Biophys. Acta. 2009;1788(8):1680-1686.
194. Lipsky BA, Holroyd KJ, ZasloffM. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin. Infect. Dis. 2008;47(12):1537-1545.
195. Ge Y, et al. In vitro antibacterial properties of pexiganan: an analog of magainin. Antimicrob. Agents Chemother., 1999;43(4):782-788.
196. Chou TG, et al. Evaluating antimicrobials and implant materials for infection prevention around transcutaneous osseointegrated implants in a rabbit model. J. Biomed. Mater. Res. A 2010;92(3): 942-952.
197. Cole AM,Waring AJ. The role of defensins in lung biology and therapy. Am. J. Respir. Med. 2002;1 (4):249-259.
198. StokmanMA,et al. Preventive intervention possibilities in radiotherapy-andchemotherapy-induced oral mucositis: results of meta-analyses. J. Dent. Res. 2006;85(8):690-700.
199. Giles FJ, et al. A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leuk. Res. 2004;28 (6):559-565.
200. Kollef M, et al. A randomized double-blind trial of iseganan in prevention of ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 2006;173(1):91-97.
201. Kim SM, et al. Indolicidin-derived antimicrobial peptide analogs with greater bacterial selectivity and requirements for antibacterial and hemolytic activities. Biochim. Biophys. Acta 2009;1794(2):185-192.
202. Lee DG, et al. Fungicidal effect of indolicidin and its interaction with phospholipid membranes. Biochem. Biophys. Res. Commun. 2003;305(2):305-310.
203. Robinson WE, Jr., et al. Anti-HIV-1 activity of indolicidin: an antimicrobial peptide from neutrophils. J. Leukoc. Biol. 1998;63(1):94-100.
204. Selsted ME, et al. Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils. J. Biol. Chem. 1992;267(7):4292-4295.
205. Schluesener HJ, et al. Leukocytic antimicrobial peptides kill autoimmune T cells. J. Neuroimmunol. 1993;47(2):199-202.
206. Rubinchik E, et al. Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models. Int. J. Antimicrob. Agents 2009;34(5):457-461.
207. Fritsche TR, et al. Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections. Antimicrob. Agents Chemother. 2008;52(3):1187-1189.
208. Kamysz W, et al. In vitro activity of synthetic antimicrobial peptides against Candida. Pol. J. Microbiol. 2006;55(4):303-307.
209. Zhang C, et al. A gene delivery approach for antimicrobials: expression of defensins. J. Drug Target 2006;14(9):646-651.
210. Pavicic MJ, vanWinkelhoff AJ, de Graaff J. Synergistic effects between amoxicillin, metronidazole, and the hydroxymetabolite of metronidazole against Actinobacillus actinomycetemcomitans. Antimicrob. Agents Chemother. 1991;35(5):961-966.
211. vanWinkelhoff AJ, Tijhof CJ, de Graaff J. Microbiological and clinical results of metronidazole plus amoxicillin therapy in Actinobacillus actinomycetemcomitans associated periodontitis. J. Periodontol. 1992;63(1):52-57.
212. van Winkelhoff AJ, Winkel EG. Systemic antibiotic therapy in severe periodontitis. Curr. Opin. Periodontol. 1997;4:35-40.
213. Christophers E, Henseler T. Contrasting disease patterns in psoriasis and atopic dermatitis. Arch. Dermatol. Res. 1987;279 (Suppl): S48-S51.
214. Fulton C, et al. Expression of natural peptide antibiotics in human skin. Lancet 1997;350 (9093):1750-1751.
215. Nomura I, et al. Cytokine milieu of atopic dermatitis: as compared to psoriasis, skin prevents induction of innate immune response genes. J. Immunol. 2003;171(6):326-329.